Both Omeros Corporation (NASDAQ:OMER) and Riot Blockchain Inc. (NASDAQ:RIOT) are each other’s competitor in the Biotechnology industry. Thus the contrast of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Omeros Corporation 21.61M 31.84 119.77M -2.48 0.00
Riot Blockchain Inc. 6.36M 5.69 55.59M -2.81 0.00

Table 1 demonstrates Omeros Corporation and Riot Blockchain Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 represents Omeros Corporation (NASDAQ:OMER) and Riot Blockchain Inc. (NASDAQ:RIOT)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Omeros Corporation -554.23% 270.2% -123.7%
Riot Blockchain Inc. -874.06% -225.6% -161.4%

Risk & Volatility

Omeros Corporation’s volatility measures that it’s 271.00% more volatile than Standard & Poor’s 500 due to its 3.71 beta. Riot Blockchain Inc. has a 3.05 beta and it is 205.00% more volatile than Standard & Poor’s 500.

Institutional and Insider Ownership

Omeros Corporation and Riot Blockchain Inc. has shares owned by institutional investors as follows: 48% and 9.8%. Insiders owned 0.4% of Omeros Corporation shares. Comparatively, Riot Blockchain Inc. has 2.1% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Omeros Corporation -0.72% -15.24% -46.46% -25.18% -31.27% -28.72%
Riot Blockchain Inc. -9.14% -41.72% -62.44% -77.28% -88.42% -94.05%

For the past year Omeros Corporation was less bearish than Riot Blockchain Inc.

Summary

Omeros Corporation beats on 9 of the 10 factors Riot Blockchain Inc.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The companyÂ’s clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington’s diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The companyÂ’s preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

Bioptix, Inc., through its subsidiary, BiOptix Diagnostics, Inc., develops enhanced surface plasmon resonance technology platform for the detection of molecular interactions. The company also focuses on animal healthcare and owns important intellectual property rights related to veterinary products. In addition, it has granted a license relating to single chain reproductive hormone technology for use in no-human mammals, which is under active development by the licensee bovine rFSH. The company was formerly known as Venaxis, Inc. and changed its name to Bioptix, Inc. in November 2016. Bioptix, Inc. was founded in 2000 and is based in Castle Rock, Colorado.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *